search
Back to results

Feasibility, Efficacy and Safety of IBS ® for Implantaiton in the PDA in Duct-dependent Cyanotic CHD

Primary Purpose

Patent Ductus Arteriosus, Duct-dependent Cyanotic Congenital Heart Disease

Status
Unknown status
Phase
Not Applicable
Locations
Malaysia
Study Type
Interventional
Intervention
Iron biocorrodable coronary scaffold system
Sponsored by
Lifetech Scientific (Shenzhen) Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Patent Ductus Arteriosus

Eligibility Criteria

undefined - 3 Months (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Weight >3.0 kg
  • Age <3 months
  • Patients with uncomplicated PDA morphology (the PDA is not tortuous i.e. relatively straight

Exclusion Criteria:

  • Weight <3 kg, age >3 months
  • Angiographic criteria-tortuous PDA
  • Family history of diseases related to iron overload or iron disorder e.g. hereditary hemochromatosis
  • Other severe congenital anomalies with life expectancy <12 months

Sites / Locations

  • Institut Jantung Negara

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

IBS implantation

Arm Description

Implantation of IBS in PDA in duct-dependent cyanotic CHD

Outcomes

Primary Outcome Measures

Number of participants for surgical repair of CHD
Patients are subjected for surgical repair of CHD
Number of Unplanned re-intervention
Unplanned re-intervention with additional stenting procedure
Death
Death before surgical repair

Secondary Outcome Measures

Full Information

First Posted
February 28, 2020
Last Updated
February 28, 2020
Sponsor
Lifetech Scientific (Shenzhen) Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT04291222
Brief Title
Feasibility, Efficacy and Safety of IBS ® for Implantaiton in the PDA in Duct-dependent Cyanotic CHD
Official Title
Feasibility, Efficacy and Safety of IBS ® for Implantaiton in the PDA in Duct-dependent Cyanotic CHD
Study Type
Interventional

2. Study Status

Record Verification Date
February 2020
Overall Recruitment Status
Unknown status
Study Start Date
December 11, 2018 (Actual)
Primary Completion Date
August 2020 (Anticipated)
Study Completion Date
August 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Lifetech Scientific (Shenzhen) Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a pilot study on feasibility, efficacy and safety of IBS ® for implantation in the PDA in duct-dependent cyanotic CHD, and its objective is to investigate the feasibility, safety and efficacy of iron resorbable stent implantation in the PDA as initial palliation of cyanotic CHD with duct-dependent PBF.
Detailed Description
Study type: Interventional, prospective, single arm, investigator initiated Study population: 10 patients Primary purpose: Treatment Follow up: Review at 1 month and thereafter 3 monthly (clinical examination and echocardiography for stent patency, SaO2 measurement. Serum Iron and Ferritin levels will be measured before procedure and at follow ups. From 6 months onwards the patients will be assessed for the need of repeat catheterization with a view of surgery or for continued observation. Study endpoints: 9 months post implant or the following: 1)Patients are subjected for surgical repair of CHD; 2)Death before surgical repair; 3)Unplanned re-intervention with additional stenting procedure.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Patent Ductus Arteriosus, Duct-dependent Cyanotic Congenital Heart Disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
IBS implantation
Arm Type
Experimental
Arm Description
Implantation of IBS in PDA in duct-dependent cyanotic CHD
Intervention Type
Device
Intervention Name(s)
Iron biocorrodable coronary scaffold system
Intervention Description
Implantation of Iron biocorrodable coronary scaffold system
Primary Outcome Measure Information:
Title
Number of participants for surgical repair of CHD
Description
Patients are subjected for surgical repair of CHD
Time Frame
9 months
Title
Number of Unplanned re-intervention
Description
Unplanned re-intervention with additional stenting procedure
Time Frame
9 months
Title
Death
Description
Death before surgical repair
Time Frame
9 months

10. Eligibility

Sex
All
Maximum Age & Unit of Time
3 Months
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Weight >3.0 kg Age <3 months Patients with uncomplicated PDA morphology (the PDA is not tortuous i.e. relatively straight Exclusion Criteria: Weight <3 kg, age >3 months Angiographic criteria-tortuous PDA Family history of diseases related to iron overload or iron disorder e.g. hereditary hemochromatosis Other severe congenital anomalies with life expectancy <12 months
Facility Information:
Facility Name
Institut Jantung Negara
City
Kuala Lumpur
Country
Malaysia

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Feasibility, Efficacy and Safety of IBS ® for Implantaiton in the PDA in Duct-dependent Cyanotic CHD

We'll reach out to this number within 24 hrs